Novartis intends to localize production of 40 drugs at its plant in St Petersburg

19 December 2017

Swiss pharma giant Novartis (NOVN: VX) intends to localize production of up to 40 drugs at its Novartis-Neva plant in the Russian St Petersburg region, according to recent statements of vice governor of St Petersburg Sergey Movchan.

Production will comprise both for generics and original drugs. The new drugs will be supplied both to the domestic and foreign markets, reports The Pharma Letter’s local correspondent.

To date, the company has already launched the production of a new an anti-inflammatory drug, the name of which is not disclosed. The launch of production took place as part of the state program "Pharma 2020", which involves replacement of drug imports in Russia by the establishment of domestic production.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK